Myriad Genetics (MYGN) surged 24% in premarket trading on Tuesday after reporting a quarterly earnings beat and outlining a 2026 revenue target of $860 million to $880 million while highlighting ...

Collaboration, partnership, and clinical integration are key.

Myriad Genetics (NASDAQ:MYGN) executives highlighted fourth quarter and full-year 2025 results alongside a slate of planned ...

Myriad Genetics delivered a solid Q4 2025 earnings beat, with positive adjusted EPS and strong test volume growth. Click for my earnings analysis of MYGN stock.

Opus Genetics targets inherited retinal diseases with one-dose AAV gene augmentations. Read why IRD stock is a Buy.

For more than a century, Mendelian genetics has shaped how we think about inheritance: one gene, one trait. It is a model that still echoes through textbooks—and one that is increasingly reaching its ...

Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported in Q4 CY2025, but sales were flat year on year at $209.8 ...

Genetics is the study of genes and how they influence characteristics and health. Through a variety of technological methods, environmental factors, and lifestyle choices, it is possible to alter some ...

The Clinical Genetics and Genetic Counseling Service at Fred Hutch Cancer Center offers cancer risk assessment for people who are at high risk of developing cancer because of their personal history ...

Why do some people feel chills when listening to music, reading poetry, or viewing a powerful work of art, while others do ...

Leads Genetics launches an advanced R&D centre in Bareilly for indigenous cattle genetics, enhancing India's dairy industry ...